Literature DB >> 24527516

[Antimicrobial activity of several drugs against extended-spectrum beta-lactamase positive Enterobacteriaceae isolates in Gifu and Aichi prefecture].

Satoshi Nakagawa1, Harumi Hisada1, Nobuhiko Nomura1, Junichi Mitsuyama1, Shigenori Matsubara2, Kazukiyo Yamaoka3, Kunitomo Watanabe4, Yuko Asano5, Hiroyuki Suematsu6, Haruki Sawamura6, Hikonori Hashido7, Yuka Yamagishi8, Hiroshige Mikamo8, Yoko Matsukawa9.   

Abstract

We investigated the antimicrobial activity of several drugs against 131 extended-spectrum beta-lactamase (ESBL) positive clinical isolates in Gifu and Aichi prefecture from 2007 to 2011. Meropenem (MEPM) and doripenem (DRPM) gave the lowest MIC50 at 0.0313 microg/mL. MEPM gave the lowest MIC90 at 0.0625 microg/mL. According to the Clinical and Laboratory Standards Institute breakpoints, the susceptible rates of carbapenems, tazobactam/piperacillin (TAZ/PIPC) and cefmetazole (CMZ) were higher than 90%. The susceptible rates of MEPM, DRPM, imipenem (IPM), TAZ/PIPC and CMZ were 98.5%, 98.5%, 94.7%, 94.7% and 92.4%. We used the PCR method and identified the molecular types of the ESBL positive isolates. Seventy-two strains had CTX-M-9 group gene and CTX-M-9 group gene is the most frequently detected. Against the CTX-M-9 group gene harboring strains which were the most common in our investigation, the susceptible rates of TAZ/PIPC, MEPM, DRPM and IPM were 100%. It is suggested that not only carbapenems but also TAZ/PIPC and CMZ are useful against infections caused by ESBL positive isolates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24527516

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  1 in total

1.  Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.

Authors:  Hiroki Namikawa; Koichi Yamada; Hiroki Fujimoto; Ken-Ichi Oinuma; Yoshihiro Tochino; Yasuhiko Takemoto; Yukihiro Kaneko; Taichi Shuto; Hiroshi Kakeya
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.